Respiratory Medicine Case Reports (Jan 2020)
Acute pneumothorax due to immunotherapy administration in non-small cell lung cancer
- Chrysanthi Sardeli,
- Paul Zarogoulidis,
- Konstantinos Romanidis,
- Panagoula Oikonomou,
- Konstantinos Sapalidis,
- Haidong Huang,
- Chong Bai,
- Wolfgang Hohenforst-Schmidt,
- Kosmas Tsakiridis,
- Bojan Zaric,
- Branislav Perin,
- Aris Ioannidis,
- Sofia Baka,
- Konstantinos Drevelegas,
- Maria Kosmidou,
- Christoforos Kosmidis
Affiliations
- Chrysanthi Sardeli
- Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
- Paul Zarogoulidis
- Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece; 3rd Department of Surgery, ‘‘AHEPA‘‘ University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece; Corresponding author. 3rd Department of Surgery, ‘‘AHEPA‘‘ University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece.
- Konstantinos Romanidis
- Second Department of Surgery, University Hospital of Alexandroupolis, Medical School, Democritus University of Thrace, Alexandroupolis, Greece
- Panagoula Oikonomou
- Second Department of Surgery, University Hospital of Alexandroupolis, Medical School, Democritus University of Thrace, Alexandroupolis, Greece
- Konstantinos Sapalidis
- 3rd Department of Surgery, ‘‘AHEPA‘‘ University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece
- Haidong Huang
- Department of Respiratory & Critical Care Medicine, Changhai Hospital, The Second Military Medical University, Shanghai, China
- Chong Bai
- Department of Respiratory & Critical Care Medicine, Changhai Hospital, The Second Military Medical University, Shanghai, China
- Wolfgang Hohenforst-Schmidt
- Sana Clinic Group Franken, Department of Cardiology / Pulmonology / Intensive Care / Nephrology, ‘‘Hof‘‘ Clinics, University of Erlangen, Hof, Germany
- Kosmas Tsakiridis
- Thoracic Surgery Department, ‘‘Interbalkan‘‘ European Medical Center, Thessaloniki, Greece
- Bojan Zaric
- Institute for Pulmonary Diseases of Vojvodina, Faculty of Medicine, University of Novi Sad, Serbia
- Branislav Perin
- Institute for Pulmonary Diseases of Vojvodina, Faculty of Medicine, University of Novi Sad, Serbia
- Aris Ioannidis
- Surgery Department, ‘‘Genesis‘‘ Private Hospital, Thessaloniki, Greece
- Sofia Baka
- Oncology Department, ‘‘Intebalkan‘‘ European Medical Center, Thessaloniki, Greece
- Konstantinos Drevelegas
- Radiology Department, ‘‘Euromedica‘‘ Private Radiology Laboratory, Thessaloniki, Greece
- Maria Kosmidou
- Internal Medicine, University Hospital of Ioannina, Ioannina, Greece
- Christoforos Kosmidis
- 3rd Department of Surgery, ‘‘AHEPA‘‘ University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece
- Journal volume & issue
-
Vol. 31
p. 101258
Abstract
Nowadays we have novel therapies for advanced stage non-small cell lung cancer. Immunotherapy has been introduced in the market for several years and until now its administration is mostly based on the programmed death-ligand 1. First line treatment with immunotherapy can be administered alone if programmed death-ligand 1 expression is ≥ 50%. All therapies for advanced stage disease have advantages and disadvantages, immunotherapy until now has presented mild adverse effects when compared to chemotherapy. However; it is known to induce inflammatory response to different tissues within the body. In our case acute pneumothorax was induced after immunotherapy administration.
